Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained

Peter Gilling,Neil Barber,Mohamed Bidair,Paul Anderson,Mark Sutton,Tev Aho,Eugene Kramolowsky,Andrew Thomas,Barrett Cowan,Ronald P. Kaufman,Andrew Trainer,Andrew Arther,Gopal Badlani,Mark Plante,Mihir Desai,Leo Doumanian,Alexis E. Te,Mark DeGuenther,Claus Roehrborn
DOI: https://doi.org/10.1007/s12325-019-00952-3
2019-04-26
Advances in Therapy
Abstract:<h3>Introduction</h3><p>To compare 2-year safety and efficacy outcomes after Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostate hyperplasia (BPH).</p><h3>Methods</h3><p>One hundred eighty-one patients with BPH were assigned at random (2:1 ratio) to either Aquablation or TURP. Patients and follow-up assessors were blinded to treatment. Assessments included the International Prostate Symptom Score (IPSS), Male Sexual Health Questionnaire (MSHQ), International Index of Erectile Function and uroflow. The focus of analysis was 2-year outcomes.</p><h3>Results</h3><p>At 2 years, IPSS scores improved by 14.7 points in the Aquablation group and 14.9 points in TURP (<em>p</em> = .8304, 95% CI for difference − 2.1 to 2.6 points). Two-year improvements in maximum flow rate (<em>Q</em><sub>max</sub>) were large in both groups at 11.2 and 8.6 cc/s for Aquablation and TURP, respectively (<em>p</em> = 0.1880, 95% CI for difference − 1.3 to 6.4). Sexual function as assessed by MSHQ was stable in the Aquablation group and decreased slightly in the TURP group. At 2 years, PSA was reduced significantly in both groups by 0.7 and 1.2 points, respectively; the reduction was similar across groups (<em>p</em> = 0.1816). Surgical retreatment rates after 12 months for Aquablation were 1.7% and 0% for TURP. Over 2 years, surgical BPH retreatment rates were 4.3% and 1.5% (<em>p</em> = 0.4219), respectively.</p><h3>Conclusion</h3><p>Two-year efficacy outcomes after TURP and Aquablation were similar, and the rate of surgical retreatment was low and similar to TURP.</p><h3>Trial Registration</h3><p>ClinicalTrials.gov no. NCT02505919.</p><h3>Funding</h3><p>PROCEPT BioRobotics.</p>
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?